Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a

AMGROS I/S

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.

Deadline

Fristen for modtagelse af bud var på 2024-04-30. Indkøbet blev offentliggjort på 2024-03-04.

Leverandører

Følgende leverandører er nævnt i tildelingsbeslutninger eller andre indkøbsdokumenter:

Hvem?

• AMGROS I/S

Hvad?

• Medicinsk udstyr, lægemidler og produkter til personlig pleje › Lægemidler

Hvor?

• Hovedstaden › Byen København
• Midtjylland › Østjylland
• Oslo og Viken › Oslo
• Ísland › Höfuðborgarsvæði

Indkøbshistorik

Dato	Dokument
2024-03-04	Udbudsbekendtgørelse
2025-06-10	Bekendtgørelse om indgåede kontrakter

Udbudsbekendtgørelse (2024-03-04)
Objekt
Omfanget af udbuddet
Titel: Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a
Kort beskrivelse:

Kontrakttype: Varer
Produkter/tjenester: Lægemidler 📦
Anslået værdi uden moms: 18 146 993 EUR 💰
Oplysninger om partier
Denne kontrakt er opdelt i partier ✅
Der kan indgives bud for et maksimalt antal partier: 14

1️⃣
Intern ID: Lot No. 1
Titel: Lot No. 1
Anslået værdi uden moms: 1 954 865 EUR 💰
Beskrivelse af udbuddet:

ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 2 ml, Unit: 16 mg, Quantity in units: Denmark: 234.183, Iceland: 9.750. ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 4 ml, Unit: 16 mg, Quantity in units: Denmark: 15.640, Iceland: 10.000. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers. If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity in units: Denmark: 234.183, Iceland: 9.750.
ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 4 ml,
Unit: 16 mg,
Quantity in units: Denmark: 15.640, Iceland: 10.000.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Varighed
Startdato: 2025-04-01 📅
Slutdato: 2029-03-31 📅
Beskrivelse
Højeste antal fornyelser: 2
Yderligere oplysninger om fornyelser:

The Contracting Authorities shall be entitled to extend the framework agreement up to two times for each pharmaceutical on unchanged terms and conditions by up to 12 months. See Framework Agreement section 8.2.

Oplysninger om valgmuligheder
Indstillinger ✅
Beskrivelse af mulighederne:

Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement. The estimated duration in section 5.1.3 is including the options for renewals. The framework agreements ordinary duration is from 1.4.2025 to 31.3.2027.

Kriterier for tildeling
Pris ✅
Titel
Partiets identifikationsnummer: LOT-0001

2️⃣
Intern ID: Lot No. 2
Titel: Lot No. 2
Anslået værdi uden moms: 1 335 120 EUR 💰
Beskrivelse af udbuddet:

ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 2 ml, Unit: 16 mg, Quantity in units: Norway: 165.000. ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 4 ml, Unit: 16 mg, Quantity in units: Norway 20.000. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers. If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity in units: Norway: 165.000.
ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 4 ml,
Unit: 16 mg,
Quantity in units: Norway 20.000.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0002

3️⃣
Intern ID: Lot No. 3
Titel: Lot No. 3
Anslået værdi uden moms: 1 294 191 EUR 💰
Beskrivelse af udbuddet:

ATC Code: H02AB09, Generic Name: Hydrocortisone, Pharmaceutical form: Injection Fluid, Strength: 100 mg, Unit: 30 mg, Quantity in units: Norway: 433.333. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 3 and 4, which are linked lot numbers. If there is only one compliant tender for either lot numbers 3 or 4, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 3, since the framework agreement for lot number 4 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 3 and 4, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 3 and 4. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Norway: 433.333.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 3 and 4, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 3 or 4, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 3, since the framework agreement for lot number 4 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 3 and 4, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 3 and 4.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0003

4️⃣
Intern ID: Lot No. 4
Titel: Lot No. 4
Anslået værdi uden moms: 1 154 257 EUR 💰
Beskrivelse af udbuddet:

ATC Code: H02AB09, Generic Name: Hydrocortisone, Pharmaceutical form: Injection Fluid, Strength: 100 mg, Unit: 30 mg, Quantity in units: Denmark: 313.146, Iceland: 73.333. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 3 and 4, which are linked lot numbers. If there is only one compliant tender for either lot numbers 3 or 4, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 3, since the framework agreement for lot number 4 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 3 and 4, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 3 and 4. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Denmark: 313.146, Iceland: 73.333.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 3 and 4, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 3 or 4, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 3, since the framework agreement for lot number 4 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 3 and 4, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 3 and 4.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0004

5️⃣
Intern ID: Lot No. 5
Titel: Lot No. 5
Anslået værdi uden moms: 474 616 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 50 ml, Unit: 200 mg, Quantity in units: Denmark: 2.760, Iceland: 350. ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 100 ml, Unit: 200 mg, Quantity in units: Denmark: 56.360, Iceland: 4.200. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 5 and 6, which are linked lot numbers. If there is only one compliant tender for either lot numbers 5 or 6, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 5, since the framework agreement for lot number 6 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 5 and 6, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 5 and 6. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity in units: Denmark: 2.760, Iceland: 350.
ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100 ml,
Unit: 200 mg,
Quantity in units: Denmark: 56.360, Iceland: 4.200.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 5 and 6, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 5 or 6, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 5, since the framework agreement for lot number 6 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 5 and 6, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 5 and 6.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0005

6️⃣
Intern ID: Lot No. 6
Titel: Lot No. 6
Anslået værdi uden moms: 203 753 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 50 ml, Unit: 200 mg, Quantity in units: Norway: 2.500. ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 100 ml, Unit: 200 mg, Quantity in units: Norway: 25.000. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 5 and 6, which are linked lot numbers. If there is only one compliant tender for either lot numbers 5 or 6, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 5, since the framework agreement for lot number 6 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 5 and 6, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 5 and 6. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity in units: Norway: 2.500.
ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100 ml,
Unit: 200 mg,
Quantity in units: Norway: 25.000.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 5 and 6, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 5 or 6, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 5, since the framework agreement for lot number 6 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 5 and 6, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 5 and 6.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0006

7️⃣
Intern ID: Lot No. 7
Titel: Lot No. 7
Anslået værdi uden moms: 262 112 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 200 ml, Unit: 200 mg, Quantity in units: Denmark: 48.400, Iceland: 999. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 7 and 8, which are linked lot numbers. If there is only one compliant tender for either lot numbers 7 or 8, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 7 and 8, the award under lot number 7 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 7, since the framework agreement for lot number 8 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 7 and 8, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 7 and 8. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity in units: Denmark: 48.400, Iceland: 999.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 7 and 8, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 7 or 8, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 7 and 8, the award under lot number 7 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 7, since the framework agreement for lot number 8 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 7 and 8, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 7 and 8.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0007

8️⃣
Intern ID: Lot No. 8
Titel: Lot No. 8
Anslået værdi uden moms: 54 150 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J02AC01, Generic Name: Fluconazole, Pharmaceutical form: Infusion Fluid, Strength: 2 mg/ml, Pack size: 200 ml, Unit: 200 mg, Quantity in units: Norway: 9.999. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 7 and 8, which are linked lot numbers. If there is only one compliant tender for either lot numbers 7 or 8, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 7 and 8, the award under lot number 7 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 7, since the framework agreement for lot number 8 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 7 and 8, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 7 and 8. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity in units: Norway: 9.999.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 7 and 8, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 7 or 8, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 7 and 8, the award under lot number 7 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 7, since the framework agreement for lot number 8 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 7 and 8, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 7 and 8.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0008

9️⃣
Intern ID: Lot No. 9
Titel: Lot No. 9
Anslået værdi uden moms: 2 205 797 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J05AB01, Generic Name: Aciclovir, Pharmaceutical form: Infusion Fluid, Strength: 25 mg/ml, Unit: 4 g, Quantity in units: Norway: 8.750. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 9 and 10, which are linked lot numbers. If there is only one compliant tender for either lot numbers 9 or 10, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 9 and 10, the award under lot number 9 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and there are several compliant tenders for both lot numbers 9 and 10, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 9, since the framework agreement for lot number 10 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 9 and 10. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Norway: 8.750.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 9 and 10, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 9 or 10, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 9 and 10, the award under lot number 9 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and there are several compliant tenders for both lot numbers 9 and 10, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 9, since the framework agreement for lot number 10 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 9 and 10.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0009

1️⃣0️⃣
Intern ID: Lot No. 10
Titel: Lot No. 10
Anslået værdi uden moms: 2 194 642 EUR 💰
Beskrivelse af udbuddet:

ATC Code: J05AB01, Generic Name: Aciclovir, Pharmaceutical form: Infusion Fluid, Strength: 25 mg/ml, Unit: 4 g, Quantity in units: Denmark: 8.662, Iceland: 44. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 9 and 10, which are linked lot numbers. If there is only one compliant tender for either lot numbers 9 or 10, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 9 and 10, the award under lot number 9 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and there are several compliant tenders for both lot numbers 9 and 10, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 9, since the framework agreement for lot number 10 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 9 and 10. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Denmark: 8.662, Iceland: 44.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 9 and 10, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 9 or 10, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 9 and 10, the award under lot number 9 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and there are several compliant tenders for both lot numbers 9 and 10, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 9, since the framework agreement for lot number 10 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 9 and 10.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0010

1️⃣1️⃣
Intern ID: Lot No. 11
Titel: Lot No. 11
Anslået værdi uden moms: 849 633 EUR 💰
Beskrivelse af udbuddet:

ATC Code: L01BA01, Generic Name: Methotrexate, Pharmaceutical form: Infusion Fluid, Strength: 100 mg/ml, Pack size: 10 ml, Unit: 11,429 mg, Quantity in units: Norway: 349.987. ATC Code: L01BA01, Generic Name: Methotrexate, Pharmaceutical form: Infusion Fluid, Strength: 100 mg/ml, Pack size: 50 ml, Unit: 11,429 mg, Quantity in units: Norway: 1.312.451. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 11 and 12, which are linked lot numbers. If there is only one compliant tender for either lot numbers 11 or 12, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 11 and 12, the award under lot number 11 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 11 and 12, and there are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 11, since the framework agreement for lot number 12 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 11 and 12. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity in units: Norway: 349.987.
ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size: 50 ml,
Unit: 11,429 mg,
Quantity in units: Norway: 1.312.451.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 11 and 12, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 11 or 12, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 11 and 12, the award under lot number 11 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 11 and 12, and there are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 11, since the framework agreement for lot number 12 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 11 and 12.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0011

1️⃣2️⃣
Intern ID: Lot No. 12
Titel: Lot No. 12
Anslået værdi uden moms: 787 664 EUR 💰
Beskrivelse af udbuddet:

ATC Code: L01BA01, Generic Name: Methotrexate, Pharmaceutical form: Infusion Fluid, Strength: 100 mg/ml, Pack size: 10 ml, Unit: 11,429 mg, Quantity in units: Denmark: 116.721, Iceland: 17.499. ATC Code: L01BA01, Generic Name: Methotrexate, Pharmaceutical form: Infusion Fluid, Strength: 100 mg/ml, Pack size: 50 ml, Unit: 11,429 mg, Quantity in units: Denmark: 1.388.574, Iceland: 61.248. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 11 and 12, which are linked lot numbers. If there is only one compliant tender for either lot numbers 11 or 12, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 11 and 12, the award under lot number 11 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 11 and 12, and there are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 11, since the framework agreement for lot number 12 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 11 and 12. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity in units: Denmark: 116.721, Iceland: 17.499.
ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size: 50 ml,
Unit: 11,429 mg,
Quantity in units: Denmark: 1.388.574, Iceland: 61.248.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 11 and 12, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 11 or 12, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 11 and 12, the award under lot number 11 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 11 and 12, and there are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 11, since the framework agreement for lot number 12 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 11 and 12.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0012

1️⃣3️⃣
Intern ID: Lot No. 13
Titel: Lot No. 13
Anslået værdi uden moms: 3 069 705 EUR 💰
Beskrivelse af udbuddet:

ATC Code: N02BE01, Generic Name: Paracetamol, Pharmaceutical form: Infusion Fluid, Strength: 10 mg/ml, Pack size: 10-50 ml, Unit: 3 g, Quantity in units: Norway: 10.000. ATC Code: N02BE01, Generic Name: Paracetamol, Pharmaceutical form: Infusion Fluid, Strength: 10 mg/ml, Pack size: 100 ml, Unit: 3 g, Quantity in units: Norway: 466.667. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 13 and 14, which are linked lot numbers. If there is only one compliant tender for either lot numbers 13 or 14, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 13 and 14, the award under lot number 13 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 13, since the framework agreement for lot number 14 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 13 and 14. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity in units: Norway: 10.000.
ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100 ml,
Unit: 3 g,
Quantity in units: Norway: 466.667.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 13 and 14, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 13 or 14, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 13 and 14, the award under lot number 13 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 13, since the framework agreement for lot number 14 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 13 and 14.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0013

1️⃣4️⃣
Intern ID: Lot No. 14
Titel: Lot No. 14
Anslået værdi uden moms: 2 306 484 EUR 💰
Beskrivelse af udbuddet:

ATC Code: N02BE01, Generic Name: Paracetamol, Pharmaceutical form: Infusion Fluid, Strength: 10 mg/ml, Pack size: 10-50 ml, Unit: 3 g, Quantity in units: Denmark: 3.525, Iceland: 417. ATC Code: N02BE01, Generic Name: Paracetamol, Pharmaceutical form: Infusion Fluid, Strength: 10 mg/ml, Pack size: 100 ml, Unit: 3 g, Quantity in units: Denmark: 323.184, Iceland: 33.333. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 13 and 14, which are linked lot numbers. If there is only one compliant tender for either lot numbers 13 or 14, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 13 and 14, the award under lot number 13 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 13, since the framework agreement for lot number 14 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 13 and 14. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Beskrivelse af udbuddet

ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity in units: Denmark: 3.525, Iceland: 417.
ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100 ml,
Unit: 3 g,
Quantity in units: Denmark: 323.184, Iceland: 33.333.
Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 13 and 14, which are linked lot numbers.
If there is only one compliant tender for either lot numbers 13 or 14, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”.
If there are several compliant tenders for both lot numbers 13 and 14, the award under lot number 13 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 13, since the framework agreement for lot number 14 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned.
If there is only one compliant tender for both lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 13 and 14.
Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Titel
Partiets identifikationsnummer: LOT-0014

Procedure
Type af procedure
Åben procedure ✅
Retsgrundlag: Direktiv 2014/24/EU
Administrative oplysninger
Frist for modtagelse af bud eller ansøgninger om deltagelse: 2024-04-30 12:00:00 📅
Betingelser for åbning af buddene: 2024-04-30 12:01:00 📅
Betingelser for åbning af buddene (sted): Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø
Betingelser for åbning af tilbud (Oplysninger om bemyndigede personer og åbningsprocedure):

Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard. The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide. In relation to section 5.1.12 it should be noted that electronic invoicing is required. The Tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened collectively after expiry of the deadline for submission of tenders. With the notice regarding the tender evaluation, the tenderers will receive a comprehensive overview of the operators that have submitted compliant tenders.

Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: engelsk 🗣️
dansk 🗣️

+ 2 mere

svensk 🗣️
norsk 🗣️

Minimumsfrist, inden for hvilken tilbudsgiveren skal opretholde tilbuddet: 11 måneder
Oplysninger om forhandling
Den ordregivende myndighed forbeholder sig ret til at tildele kontrakten på grundlag af de første tilbud uden at føre forhandlinger ✅
Oplysninger om en rammeaftale eller et dynamisk indkøbssystem
Rammeaftale med flere operatører ✅
Udbudsbetingelser
Åbningsdato: 2024-04-30 12:01:00 📅
Sted: Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø
Yderligere oplysninger:

Elektronisk fakturering: Tilladt
Der vil blive anvendt elektronisk bestilling ✅
Der vil blive anvendt elektronisk betaling ✅
Frist for anmodning om yderligere oplysninger: 2024-04-19 📅
Kontrakten indeholder gennemførelsesbetingelser ✅

Juridiske, økonomiske, finansielle og tekniske oplysninger
Betingelser for deltagelse
Den juridiske form, som den sammenslutning af økonomiske aktører, der skal have kontrakten, skal have:

Reference is made to the provisions of the draft framework agreement. No specific legal form is required. If the contract is awarded to a group of suppliers, each participant must undertake joint and several liability and appoint a joint representative.

Betingelser i forbindelse med kontrakten
Betingelser for opfyldelse af kontrakten:

The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA. The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 17 February 2025 in order to ensure supply from the beginning of the Purchase Period. The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.

Betingelser for deltagelse
Udelukkelsesgrund:

Betaling af skatter og afgifter

Betaling af socialsikringsbidrag

Børnearbejde og andre former for menneskehandel

+ 10 mere

Deltagelse i en kriminel organisation

Direkte eller indirekte involvering i forberedelsen af denne udbudsprocedure

Har afgivet urigtige oplysninger eller tilbageholdt oplysninger, som ikke var i stand til at fremlægge de krævede dokumenter og indhentet fortrolige oplysninger i forbindelse med denne procedure

Hvidvaskning af penge eller finansiering af terrorisme

Interessekonflikt som følge af deltagelse i udbudsproceduren

Korruption

Rent nationale udelukkelsesgrunde

Skyldig i alvorlige forsømmelser i forbindelse med udøvelsen af erhvervet

Svig

Terrorhandlinger eller strafbare handlinger med forbindelse til terroraktivitet

Beskrivelse af udelukkelsesgrunde:

The Danish Public Procurement Act, §135, section 1, no.…

… 2

… 6

… 3

… 1

The Danish Public Procurement Act, §136, no. 2

The Danish Public Procurement Act, §135, section…

… 3

… 1, no. 4

… 1, no. 5

The Danish Public Procurement Act, §136, no.…

… 3

… 1

… 4

The Danish Public Procurement Act, §134a

Ordregivende myndighed
Navn og adresser
Navn: Amgros I/S
Nationalt registreringsnummer: 14479880
Postadresse: Dampfærgevej 22
Postnummer: 2100
Postby: København Ø
Region: Byen København 🏙️
Land: Danmark 🇩🇰
Enhed: Flemming Sonne
E-mail: amgros@amgros.dk 📧
Telefon: +45 88713000 📞
URL: https://amgros.dk 🌏
Gruppeleder ✅
Den ordregivende myndigheds type
Offentligretligt organ
Hovedaktivitet
Sundhed
Oplysninger om fælles indkøb
Kontrakten omfatter fælles indkøb ✅
Kontrakten tildeles af en indkøbscentral ✅
Kommunikation
URL til dokumenter: https://levportal.amgros.dk/Sider/Default.aspx 🌏
URL for deltagelse: https://levportal.amgros.dk/Sider/Default.aspx 🌏
Elektronisk indgivelse: Påkrævet

Supplerende oplysninger
Yderligere oplysninger

The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see section 5.1.12. The Contracting Authorities have considered whether the tender group could be further subdivided. The Contracting Authorities have deemed that this is not the case based on the considerations of economies of scale, which will not be realizable with a further subdivision as well as costs and patient safety considerations related to the subsequent management of contract- and pharmaceuticals. In relation to sections 2.1.3 and 5.1.5 it should be noted that the estimated value indicated in section 2.1.3 is the total estimated value of all lot numbers for the duration of the framework agreement, including the option of renewal, see section 5.1.4. Section 5.1.5 sets out the estimated value for each lot number, including the option of renewal, see section 5.1.4. The value is based on the AIP ("Apotekernes Indkøbspris" published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may deviate significantly from the estimate, see section 5.1, paragraph 5.6 of the tender specifications and clause 4.2 of the framework agreement. When submitting a tender, suppliers must use the European Single Procurement Document (ESPD) in the tendering system for the declaration regarding the compulsory grounds for exclusion set out in sections 135-136 of the Danish Public Procurement Act (udbudsloven) (the Act can be found at www.retsinformation.dk). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the "Instructions for the European Single Procurement Document" drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the Contracting Authorities intend to award the framework agreement must also, before the award, provide documentation to the Contracting Authorities regarding the absence of compulsory groundsfor exclusion as set out in sections 152-153 of the Public Procurement Act. The Contracting Authorities are not entitled to exclude a supplier who is subject to one or more of the mandatory exclusion grounds set out insections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to one or more of the grounds for exclusion set out in section138 of the Public Procurement Act. The Contracting Authorities reserve the right to carry out a so-called "self-cleaning" process if relevant. The supplier is required to confirm that they do not fall under the exclusion criteria outlined in section 134a of the Danish Public Procurement Act. However, they are not required to provide documentation to support this confirmation. It is noted that this tender falls under Article 5k of Regulation (EU) No. 833/2014, as amended by Regulation (EU) 2022/1269, which prohibits the awarding of contracts to Russian companies and Russian-controlled entities. The contracting authority reserves the right, at any stage of the tender process, to demand documentation proving that economic operators are not subject to this ban. This may include documentation regarding the location of establishment and ownership of the entities involved, as well as any of their subcontractors.

Yderligere oplysninger

The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see section 5.1.12. The Contracting Authorities have considered whether the tender group could be further subdivided. The Contracting Authorities have deemed that this is not the case based on the considerations of economies of scale, which will not be realizable with a further subdivision as well as costs and patient safety considerations related to the subsequent management of contract- and pharmaceuticals. In relation to sections 2.1.3 and 5.1.5 it should be noted that the estimated value indicated in section 2.1.3 is the total estimated value of all lot numbers for the duration of the framework agreement, including the option of renewal, see section 5.1.4. Section 5.1.5 sets out the estimated value for each lot number, including the option of renewal, see section 5.1.4. The value is based on the AIP ("Apotekernes Indkøbspris" published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may deviate significantly from the estimate, see section 5.1, paragraph 5.6 of the tender specifications and clause 4.2 of the framework agreement.
When submitting a tender, suppliers must use the European Single Procurement Document (ESPD) in the tendering system for the declaration regarding the compulsory grounds for exclusion set out in sections 135-136 of the Danish Public Procurement Act (udbudsloven) (the Act can be found at www.retsinformation.dk). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the "Instructions for the European Single Procurement Document" drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the Contracting Authorities intend to award the framework agreement must also, before the award, provide documentation to the Contracting Authorities regarding the absence of compulsory groundsfor exclusion as set out in sections 152-153 of the Public Procurement Act. The Contracting Authorities are not entitled to exclude a supplier who is subject to one or more of the mandatory exclusion grounds set out insections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to one or more of the grounds for exclusion set out in section138 of the Public Procurement Act. The Contracting Authorities reserve the right to carry out a so-called "self-cleaning" process if relevant.
The supplier is required to confirm that they do not fall under the exclusion criteria outlined in section 134a of the Danish Public Procurement Act. However, they are not required to provide documentation to support this confirmation. It is noted that this tender falls under Article 5k of Regulation (EU) No. 833/2014, as amended by Regulation (EU) 2022/1269, which prohibits the awarding of contracts to Russian companies and Russian-controlled entities. The contracting authority reserves the right, at any stage of the tender process, to demand documentation proving that economic operators are not subject to this ban. This may include documentation regarding the location of establishment and ownership of the entities involved, as well as any of their subcontractors.

Gennemgå organ
Navn: Klagenævnet for Udbud
Nationalt registreringsnummer: 37795526
Postadresse: Nævnenes Hus
Toldboden 2
Postnummer: 8800
Postby: Viborg
Region: Østjylland 🏙️
Land: Danmark 🇩🇰
E-mail: klfu@naevneneshus.dk 📧
Telefon: +45 72405600 📞
URL: https://klfu.naevneneshus.dk 🌏
Tjeneste, hvorfra der kan indhentes oplysninger om klageproceduren
Navn: Konkurrence- og Forbrugerstyrelsen
Nationalt registreringsnummer: 10294819
Postadresse: Carl Jacobsens vej 35
Postnummer: 2500
Postby: Valby
Region: Byen København 🏙️
E-mail: kfst@kfst.dk 📧
Telefon: +45 41715000 📞
URL: http://www.kfst.dk 🌏
Gennemgangsprocedure
Præcise oplysninger om fristerne for gennemgangsprocedurer:

Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no. 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints: Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see section 7(2), para.(3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.

Oplysninger om elektroniske arbejdsgange
Elektronisk fakturering vil blive accepteret
Kilde: OJS 2024/S 046-134266 (2024-03-04)

Bekendtgørelse om indgåede kontrakter (2025-06-10)
Objekt
Omfanget af udbuddet
Anslået værdi uden moms: 18 146 993 EUR 💰
Rammeaftalernes maksimumværdi i denne bekendtgørelse: 18 750 000 EUR 💰
Beskrivelse
Anslået værdi uden moms: 1 954 865 EUR 💰
Land: Danmark 🇩🇰
Sted for udførelsen: Byen København 🏙️
Anslået værdi uden moms: 1 335 120 EUR 💰
1 294 191 EUR 💰
1 154 257 EUR 💰
474 616 EUR 💰
203 753 EUR 💰
262 112 EUR 💰
54 150 EUR 💰
2 205 797 EUR 💰
2 194 642 EUR 💰
849 633 EUR 💰
787 664 EUR 💰
3 069 705 EUR 💰
2 306 484 EUR 💰

Tildeling af kontrakt

1️⃣
Der tildeles en kontrakt/et parti ✅
Partiets identifikationsnummer: LOT-0001
Kontraktnummer: Lot number 1 - Fresenius Kabi - Bidding No. 40605
Dato for indgåelse af kontrakten: 2024-09-30 📅
Oplysninger om udbud
Antal modtagne bud: 2
Antal bud, der er modtaget ad elektronisk vej: 2
Antal modtagne bud fra SMV'er: 2
Antal modtagne bud fra bydende fra lande uden for EU: 0
Antal modtagne bud fra tilbudsgivere fra andre EU-medlemsstater: 1
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 2 000 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40609
ID for delkontrakt eller gruppe af delkontrakter: LOT-0001
Oplysninger om udbud
Navn på tilbudsgiver: Accord Healthcare AB
Navn og adresse på kontrahenten
Navn: Accord Healthcare A/S
Nationalt registreringsnummer: 556810-0258
Postadresse: Frösundaviks Allé 1
Postnummer: 169 70
Postby: Solna
Region: Stockholms län 🏙️
Land: Sverige 🇸🇪
E-mail: info_sweden@accord-healthcare.com 📧
Telefon: +46 86240025 📞
URL: https://www.accord-healthcare.com/se/ 🌏
Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Kontraktens/parcellens samlede værdi: 438 120 EUR 💰
Tilbud – Identifikator: Bidding no. 40605
Oplysninger om udbud
Navn på tilbudsgiver: Fresenius Kabi
Navn og adresse på kontrahenten
Navn: Fresenius Kabi
Nationalt registreringsnummer: 21347809
Postadresse: Islands Brygge 57
Postnummer: 2300
Postby: København S
Region: Byen København 🏙️
Land: Danmark 🇩🇰
E-mail: info-dk@fresenius-kabi.com 📧
Telefon: 33181600 📞
URL: https://www.fresenius-kabi.dk 🌏

2️⃣
Partiets identifikationsnummer: LOT-0002
Oplysninger om udbud
Antal modtagne bud: 3
Antal bud, der er modtaget ad elektronisk vej: 3
Antal modtagne bud fra SMV'er: 3
Antal modtagne bud fra tilbudsgivere fra andre EU-medlemsstater: 2
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 1 400 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40606
ID for delkontrakt eller gruppe af delkontrakter: LOT-0002
Tilbud – Identifikator: Bidding no. 40610
Kontraktens/parcellens samlede værdi: 816 960 EUR 💰
Tilbud – Identifikator: Bidding no. 40631
Oplysninger om udbud
Navn på tilbudsgiver: Hameln Pharma ApS
Navn og adresse på kontrahenten
Navn: Hameln Pharma ApS
Nationalt registreringsnummer: 39720213
Postadresse: Naverland 22
Postnummer: 2600
Postby: Glostrup
Region: Københavns omegn 🏙️
E-mail: rp@hameln-pharma.dk 📧
Telefon: 5171 7547 📞
URL: https://www.hameln-pharma.com 🌏

3️⃣
Partiets identifikationsnummer: LOT-0003
Oplysninger om udbud
Antal modtagne bud: 1
Antal bud, der er modtaget ad elektronisk vej: 1
Antal modtagne bud fra SMV'er: 1
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 1 300 000 EUR 💰
Kontraktens/parcellens samlede værdi: 932 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40625
ID for delkontrakt eller gruppe af delkontrakter: LOT-0003
Oplysninger om udbud
Navn på tilbudsgiver: Pfizer ApS
Navn og adresse på kontrahenten
Navn: Pfizer ApS
Nationalt registreringsnummer: 66351912
Postadresse: Lautrupvang 8
Postnummer: 2750
Postby: Ballerup
E-mail: medical.information@pfizer.com 📧
Telefon: +45 44201100 📞
URL: https://www.pfizer.dk 🌏

4️⃣
Partiets identifikationsnummer: LOT-0004
Oplysninger om udbud
Antal modtagne bud fra tilbudsgivere fra andre EU-medlemsstater: 0
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 1 200 000 EUR 💰
Kontraktens/parcellens samlede værdi: 820 799 EUR 💰
Tilbud – Identifikator: Bidding no. 40626
ID for delkontrakt eller gruppe af delkontrakter: LOT-0004

5️⃣
Partiets identifikationsnummer: LOT-0005
Rammeaftalens maksimumværdi: 500 000 EUR 💰
Kontraktens/parcellens samlede værdi: 79 008 EUR 💰
Tilbud – Identifikator: Bidding no. 40607
ID for delkontrakt eller gruppe af delkontrakter: LOT-0005
Tilbud – Identifikator: Bidding no. 40632
Oplysninger om udbud
Navn på tilbudsgiver: B. Braun Medical A/S
Navn og adresse på kontrahenten
Navn: B. Braun Medical A/S
Nationalt registreringsnummer: 20343249
Postadresse: Dirch Passers Alle 27, 3 sal
Postnummer: 2000
Postby: Frederiksberg
E-mail: kundeservice-dk@bbraun.com 📧
Telefon: 33313141 📞
URL: https://bbraun.dk 🌏

6️⃣
Partiets identifikationsnummer: LOT-0006
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 250 000 EUR 💰
Kontraktens/parcellens samlede værdi: 324 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40618
ID for delkontrakt eller gruppe af delkontrakter: LOT-0006
Oplysninger om udbud
Navn på tilbudsgiver: B. Braun Medical AS
Navn og adresse på kontrahenten
Navn: B. Braun Medical AS
Nationalt registreringsnummer: 914 113 172
Postadresse: Mathilde Henriksens vei 1
Postnummer: N-3142
Postby: Vestskogen
Region: Østfold 🏙️
Land: Norge 🇳🇴
E-mail: kundeservice.no@bbraun.com 📧
Telefon: +47 33 35 18 00 📞
URL: https://www.bbraun.no 🌏

7️⃣
Partiets identifikationsnummer: LOT-0007
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 300 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40633
ID for delkontrakt eller gruppe af delkontrakter: LOT-0007
Kontraktens/parcellens samlede værdi: 81 782 EUR 💰
Tilbud – Identifikator: Bidding no. 40608

8️⃣
Oplysninger om ikke-tilskudsgivende
Der blev ikke modtaget nogen bud eller ansøgninger om deltagelse, eller alle blev afvist
Årsagen til at der ikke udvælges en vinder: Der er ikke modtaget nogen tilbud, ansøgninger om deltagelse eller projekter
Partiets identifikationsnummer: LOT-0008
Oplysninger om udbud
Antal modtagne bud: 0
Antal bud, der er modtaget ad elektronisk vej: 0
Antal modtagne bud fra SMV'er: 0

9️⃣
Partiets identifikationsnummer: LOT-0009
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 2 300 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 517 400 EUR 💰
Tilbud – Identifikator: Bidding no. 40611
ID for delkontrakt eller gruppe af delkontrakter: LOT-0009

1️⃣0️⃣
Partiets identifikationsnummer: LOT-0010
Rammeaftalens maksimumværdi: 2 200 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 936 740 EUR 💰
Tilbud – Identifikator: Bidding no. 40612
ID for delkontrakt eller gruppe af delkontrakter: LOT-0010

1️⃣1️⃣
Partiets identifikationsnummer: LOT-0011
Rammeaftalens maksimumværdi: 900 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 128 980 EUR 💰
Tilbud – Identifikator: Bidding no. 40615
ID for delkontrakt eller gruppe af delkontrakter: LOT-0011
Oplysninger om udbud
Navn på tilbudsgiver: Sandoz A/S
Navn og adresse på kontrahenten
Navn: Sandoz A/S
Nationalt registreringsnummer: 27744532
Postadresse: Edvard Thomsens Vej 14
E-mail: info.sandoz-dk@sandoz.com 📧
Telefon: 63951000 📞
URL: https://www.sandoz.dk 🌏

1️⃣2️⃣
Partiets identifikationsnummer: LOT-0012
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 800 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 375 722 EUR 💰
Tilbud – Identifikator: Bidding no. 40616
ID for delkontrakt eller gruppe af delkontrakter: LOT-0012

1️⃣3️⃣
Partiets identifikationsnummer: LOT-0013
Rammeaftalens maksimumværdi: 3 100 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 859 000 EUR 💰
Tilbud – Identifikator: Bidding no. 40619
ID for delkontrakt eller gruppe af delkontrakter: LOT-0013
Tilbud – Identifikator: Bidding no. 40603
Oplysninger om udbud
Navn på tilbudsgiver: Baxter A/S
Navn og adresse på kontrahenten
Navn: Baxter A/S
Nationalt registreringsnummer: 72246012
Postadresse: Tobaksvejen 23A
Postnummer: 2860
Postby: Søborg
E-mail: kundeservice_danmark@baxter.com 📧
Telefon: 4816 6400 📞
URL: http://www.baxter.dk 🌏

1️⃣4️⃣
Partiets identifikationsnummer: LOT-0014
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Rammeaftalens maksimumværdi: 2 400 000 EUR 💰
Kontraktens/parcellens samlede værdi: 1 194 690 EUR 💰
Tilbud – Identifikator: Bidding no. 40604
ID for delkontrakt eller gruppe af delkontrakter: LOT-0014
Kilde: OJS 2025/S 110-373008 (2025-06-10)

Nye indkøb inden for beslægtede kategorier 🆕

Medicinsk udstyr, lægemidler og produkter til personlig pleje (>20 nye indkøb)

Lægemidler (12)